Quanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced plans to participate in the upcoming 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force in San Francisco, California from November 29 to December 2, 2022. Quanterix CEO Masoud Toloue is scheduled to...

Click to view original post